Advertisement

Treatment of CNV secondary to presumed ocular histoplasmosis with intravitreal aflibercept 2.0 mg injection

      Abstract

      Objective

      To assess the efficacy and safety of intravitreal aflibercept injection in the treatment of CNV secondary to presumed ocular histoplasmosis syndrome (POHS).

      Purpose

      To assess safety of intravitreal aflibercept for the treatment of CNV secondary to presumed ocular histoplasmosis syndrome.

      Methods

      Masked, open-label, prospective study. Five subjects will receive 2.0 mg aflibercept injection every 8 weeks with 3 initial monthly doses over a 12 month period.

      Results

      No adverse systemic or ocular were reported. At month six, the mean visual acuity improved by 7.8 ETDRS letters, mean central subfoveal thickness decreased by 38.8 microns and mean OCT volume decreased by 0.076 mm3 . At month twelve, the mean visual acuity improved by12.4 ETDRS letters, mean central subfoveal thickness decreased by 34.6 microns and mean OCT volume decreased by 0.576 mm3.

      Conclusion

      The use of intravitreal 2.0 mg aflibercept injection for the treatment of CNV secondary to presumed ocular histoplasmosis syndrome yielded no systemic or ocular adverse events and produced improvement in visual acuity and reduction of OCT thickness and volume.

      Résumé

      Objectif

      Évaluer l’efficacité et l’innocuité de l’aflibercept intravitréen pour le traitement de la néovascularisation choroïdienne (NVC) secondaire au syndrome d’histoplasmose oculaire.

      Nature

      Étude prospective ouverte à l’insu.

      Méthodes

      Cinq sujets ont reçu 2,0 mg d’aflibercept intravitréen aux 8 semaines, avec 3 doses mensuelles initiales, sur une période de 12 mois.

      Résultats

      Aucun événement indésirable, d’ordre systémique ou oculaire, n’a été noté. Au sixième mois, l’acuité visuelle moyenne s’était améliorée de 7,8 lettres ETDRS, l’épaisseur sous-fovéale centrale moyenne avait diminué de 38,8 microns et le volume TCO moyen avait diminué de 0,076 mm3. Au douzième mois, l’acuité visuelle moyenne s’était améliorée de 12,4 lettres ETDRS, l’épaisseur sous-fovéale centrale moyenne avait diminué de 34,6 microns et le volume TCO moyen avait diminué de 0,576 mm3.

      Conclusion

      L’administration de doses de 2,0 mg d’aflibercept intravitréen pour le traitement de la NVC secondaire au syndrome d’histoplasmose oculaire n’a donné lieu à aucun événement indésirable, d’ordre systémique ou oculaire, et a produit une amélioration de l’acuité visuelle et une réduction de l’épaisseur et du volume mesurés par TCO.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Olk R.J.
        • Burgess D.B.
        • McCormick P.A.
        Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome.
        Ophthalmology. 1984; 91: 1592
        • Kleiner R.C.
        • Ratner C.M.
        • Enger C.
        • et al.
        Subfoveal neovascularization in the ocular histoplasmosis syndrome: a natural history study.
        Retina. 1988; 8: 225
      1. Ocular Histoplasmosis Study. Argon laser photocoagulation for ocular histoplasmosis: results of a randomized clinical trial. Arch Ophthalmol. 1983;101:1347–57.
      2. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis: results of a randomized clinical trial. Arch Ophthalmol. 1987;105:1499–1507.
        • Bass E.B.
        • Gilson M.M.
        • Mangione C.M.
        • et al.
        Surgical removal vs observation for idiopathic or ocular histoplasmosis syndrome-associated subfoveal choroidal neovascularization: Vision Preference Value Scale findings from the randomized SST Group H Trial: SST Report No.17.
        Arch Ophthalmol. 2008; 126: 1626-1632
        • Hawkins B.S.
        • Bressler N.M.
        • Bressler S.B.
        • et al.
        Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST Report No. 9.
        Arch Ophthalmol. 2004; 122: 1597-1611
        • Berger A.S.
        • Conway M.
        • Del Priore L.V.
        • et al.
        Submacular surgery for subfoveal choroidal neovascular membranes in patients with presumed ocular histoplasmosis.
        Arch Ophthalmol. 1997; 115: 991-996
        • Thomas M.A.
        • Dickinson J.D.
        • Melberg N.S.
        • et al.
        Visual results after surgical removal of subfoveal choroidal neovascular membranes.
        Ophthalmology. 1994; 101: 1384-1396
        • Holekamp N.M.
        • Thomas M.A.
        • Dickinson J.D.
        • et al.
        Surgical removal of subfoveal choroidal neovascularization in presumed ocular histoplasmosis: stability of early visual results.
        Ophthalmology. 1997; 104: 22-26
        • Shah G.K.
        • Blinder K.J.
        • Hariprasad S.M.
        • et al.
        Photodynamic therapy for juxtafoveal chorodial neovascularization due to ocular histoplasmosis syndrome.
        Retina. 2005; 25: 26-32
        • Busquets M.A.
        • Shah G.K.
        • Wickens J.
        • et al.
        Ocular photodynamic therapy with verteporfin for choroidal neovascularization secondary to ocular histoplasmosis syndrome.
        Retina. 2003; 23: 299-306
        • Schadlu R.
        • Blinder K.J.
        • Shah G.K.
        • et al.
        Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis.
        Am J Ophthalmol. 2008; 145: 875-878
        • Ramaiya K.J.
        • Blinder K.J.
        • Ciulla T.
        • et al.
        Ranibizumab versus photodynamic therapy for presumed ocular histoplasmosis.
        Ophthalmic Surg Lasers Imaging Retina. 2013; 44: 17-21
        • Rechtman E.
        • Allen V.D.
        • Danis R.P.
        • et al.
        Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome.
        Am J Ophthalmol. 2003; 136: 739-741
        • Martidis A.
        • Miller D.G.
        • Ciulla T.A.
        • et al.
        Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization.
        J Ocul Pharmacol Ther. 1999; 15: 425-428
        • Liu J.C.
        • Boldt H.C.
        • Folk J.C.
        • et al.
        Photodynamic therapy of subfoveal and juxtafoveal choroidal neovascularization in ocular histoplasmosis syndrome: a retrospective case series.
        Retina. 2004; 24: 863-870
        • Nielsen J.S.
        • Fick T.A.
        • Saggau D.D.
        • et al.
        Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to ocular histoplasmosis syndrome.
        Retina. 2012; 32: 468-472
        • Ehrlich R.
        • Ciulla T.A.
        • Matura R.
        • et al.
        Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular hisotplasmosis syndrome.
        Retina. 2009; 29: 1418-1423
        • Cionni D.A.
        • Lewis S.A.
        • Petersen M.R.
        • et al.
        Analysis of outcomes for intravitreal bevacizumab in the treatment of chorodial neovascularization secondary to ocular histoplasmosis.
        Ophthalmology. 2012; 119: 327-332